Tags : Type-2 diabetes

Eli Lilly and Boehringer Ingelheim’s Triple Regimen Receive the US

Shots: The US FDA has approved Trijardy XR which includes Jardiance (empagliflozin), Tradjenta (linagliptin) and metformin hydrochloride extended-release to lower blood sugar in adults with T2D, along with diet and exercise The approval is based on Trijardy XR assessing the bioequivalence of Trijardy XR and their individual components in healthy adults, demonstrating a consistent safety […]Read More

Novo Nordisk Signs a Five-Year Agreement with UVA Center for

Shots: UVA in collaboration with Novo Nordisk to co-develop virtual patient modeling for T2D patients. The collaboration will utilize UVA’s work and insights on patient simulation and data-driven models within diabetes and will initially have 15 employees with an expectation of increment The focus of the collaboration is developing ‘virtual innovation lab’ for gaining deep […]Read More

Lannett Reports Results of Biosimilar Insulin Glargine in Human Clinical

Shots: The first clinical study in humans involves evaluation of PK/PD of the Lannett/HEC-insulin glargine vs the reference product, Sanofi’s US approved Lantus after a single SC dose in 27 healthy male adult candidates The study resulted in meeting all 1EPs i.e, demonstrating bio-similarity to Sanofi’s Lantus and is safe and well-tolerated with no SAEs […]Read More

Abbott Collaborates with Omada Health to Provide Integrated Digital Health

Shots: The collaboration integrates Abbott’s FreeStyle Libre system, a CGM technology, with Omada Health’s digital care program focusing to create a new paradigm for patients with T2D The integrated solution with Omada expand access to FreeStyle Libre and provide real-time glucose data and actionable information for patients to better manage their diabetes and guide personalized […]Read More